Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Anatomic Stage IV Breast Cancer AJCC V8Metastatic Breast CarcinomaRecurrent Breast Carcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyRadiation: Gallium Ga 68-DOTATATEDrug: Lutetium Lu 177 DotatateProcedure: Positron Emission Tomography
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04529044
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Not Applicable
Recruiting
- Conditions
- Hematopoietic and Lymphoid System NeoplasmBreast Ductal Carcinoma In SituBRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeLynch SyndromeHereditary Neoplastic SyndromeMalignant Solid Neoplasm
- Interventions
- Procedure: Biospecimen CollectionOther: Genetic CounselingOther: Genetic TestingOther: Survey Administration
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27500
- Registration Number
- NCT04494945
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Providence Portland Medical Center, Portland, Oregon, United States
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC V8Anatomic Stage IA Breast Cancer AJCC V8Anatomic Stage IB Breast Cancer AJCC V8Anatomic Stage II Breast Cancer AJCC V8Anatomic Stage IIA Breast Cancer AJCC V8Anatomic Stage IIB Breast Cancer AJCC V8Anatomic Stage IIIA Breast Cancer AJCC V8HER2 Negative Breast AdenocarcinomaHormone Receptor Positive Breast AdenocarcinomaInvasive Breast Carcinoma
- Interventions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT04481113
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy
Phase 2
Terminated
- Conditions
- LymphomaMalignant Solid NeoplasmPlasma Cell Myeloma
- Interventions
- Drug: Xisomab 3G3
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04465760
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Phase 2
Withdrawn
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSymptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Drug: Lopinavir/RitonavirDrug: Placebo AdministrationOther: Questionnaire Administration
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT04455958
Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Terminated
- Conditions
- Stage I Pancreatic Cancer AJCC v8Pancreatic Ductal AdenocarcinomaStage IA Pancreatic Cancer AJCC v8Stage IB Pancreatic Cancer AJCC v8
- Interventions
- Device: Activity MonitorOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT04400903
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Virtual Reality for the Education of Cancer Patients Undergoing Radiation Therapy
Not Applicable
Terminated
- Conditions
- Malignant Neoplasm
- Interventions
- Other: Educational InterventionOther: Survey Administration
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT04278534
- Locations
- 🇺🇸
Compass Oncology Rose Quarter, Portland, Oregon, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Castration-Sensitive Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Carcinoma
- Interventions
- Drug: Abiraterone AcetateDrug: Antiandrogen TherapyDrug: ApalutamideDrug: PrednisoneProcedure: Computed TomographyProcedure: Bone ScanProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT04267887
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
Phase 2
Active, not recruiting
- Conditions
- Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Liver and Intrahepatic Bile Duct CarcinomaStage III Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: DexamethasoneDrug: FloxuridineDevice: Implanted Medical DeviceDrug: IrinotecanDrug: LeucovorinDrug: OxaliplatinOther: Quality-of-Life Assessment
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04251715
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Progressive Resistance Training for the Improvement of Physical Function
Not Applicable
Completed
- Conditions
- Sarcoma
- Interventions
- Other: Exercise CounselingOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationOther: Resistance Training
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04247425
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath